OXNARD, California and
TEL AVIV, Israel, July 11, 2017 /PRNewswire/ -- CURE
Pharmaceutical (OTCQB: CURR), ("CURE"), a leading disruptive drug
delivery technology and pharmaceutical cannabinoid molecule
development company and Therapix Biosciences (NASDAQ: Ltd. (Nasdaq:
TRPX), ("Therapix"), a specialty clinical-stage pharmaceutical
company dedicated to the development of cannabinoid-based drugs
headquartered in Israel, announced
today that they signed a memorandum of understanding (MOU) to enter
into a research collaboration with Israel's largest and leading private medical
services center, Assuta Medical Centers, Ltd., ("Assuta"). The
Companies will collaborate to advance, research, develop and
commercialize potential therapeutic products in the fields of
personalized medicine and cannabinoids.
"As CURE focuses on targeting unmet needs in traditional
pharmaceutical markets that could be disrupted by cannabinoid-based
options, we are continuously looking to help bring new therapeutic
cannabinoid-based products to market and further efforts toward the
creation of personalized medicine," said Robert Davidson, CEO of CURE Pharmaceutical.
"Our new collaboration with Therapix and Assuta, two leading
companies in Israel, a Country
that is at the forefront of cannabinoid-based research in the
world, is the perfect place to start the development of these
products."
Dr. Ascher Shmulewitz, Chairman
of Therapix, added, "CURE is the ideal partner for us to enter this
promising and cutting-edge personalized cannabinoid-based
therapeutics; this deal has all the signs of a fruitful
venture."
As agreed to in the MOU, the Companies intend to formalize the
pooling of professional, scientific, financial resources and
expertise, in order to benefit from each of its respective
advantages and capabilities to develop new therapeutic products in
the fields of personalized medicine and cannabinoids. Specifically,
CURE and Therapix will provide support and expertise in the
development of pharmaceutical products, while Assuta will support
the early research and development of potential projects through
its research and facilities.
"Assuta is happy to enter into the MOU with CURE and Therapix,
and I am confident that the parties' cooperation will be a
successful one, with many other projects to follow," said Professor
Ari Shamiss, CEO of Assuta. "This
new collaboration is yet another step Assuta is taking in the
innovation world, and one of many steps to be taken by Assuta in
the field of biopharma."
About CURE Pharmaceutical
Headquartered in Oxnard,
California, CURE Pharmaceutical (OTC:CURE) is a fully
integrated specialty pharmaceutical/bioscience company that
leverages disruptive proprietary drug delivery technologies for a
broad range of molecules serving the biopharmaceutical,
veterinarian, medical foods and pharmaceutical cannabis markets.
CURE develops its patented and proprietary delivery system
(CureFilm™), the most advanced oral thin film on the market today,
from its industry leading full service cGMP manufacturing facility.
The Company's mission is to deliver proven drugs in a fast and
efficient manner and to improve quality of life.
For more information about CURE Pharmaceutical, please visit its
website at www.curepharmaceutical.com.
About Therapix Biosciences Ltd.
Therapix
Biosciences Ltd. (Nasdaq:TRPX) is a specialty clinical-stage
pharmaceutical company focused on developing technologies and
therapeutics based on cannabinoid pharmaceuticals. The Company's
clinical pipeline assets follow a de-risked 505(b)(2) regulatory
pathway benefitting from Therapix's unique proprietary formulations
based on repurposing an FDA approved synthetic cannabinoid
(dronabinol). Therapix's lead compound, THX-TS01, is currently in
Phase 2 clinical trials for Tourette's Syndrome and the Company
intends to initiate a Phase 1 clinical study of THX-ULD01 for the
treatment of Mild Cognitive Impairment, for which no FDA-approved
therapies currently exist. Please visit our website for more
information at www.therapixbio.com.
About Assuta Medical Centers
Assuta Medical Centers
(https://www.assuta.co.il/en/) is the largest private hospital
network in Israel operating 8
hospitals and medical centers from north to south. Owned by Maccabi
Healthcare, the second largest HMO in Israel, Assuta accounts for about 15% of the
surgeries in Israel and takes care
of the health of more than 1 million patients yearly. Assuta holds
JCI quality accreditation with excellence and its service standards
are ranked as top tier by the ministry of health.
Forward-looking statements
This press release contains
forward-looking statements, which are subject to risks and
uncertainties. All statements, other than statements of fact,
including those statements with respect to the Company's business
development, are forward-looking statements. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. We undertake no obligation to publicly update
or revise any forward-looking statements.
Public Relations Contact
Andrew Hard
Chief Executive Officer
CMW Media
andrew.hard@cmwmedia.com
P. +1888 829-0070
www.cmwmedia.com
Investor Relations Contact
Shiwei
Yin, Grayling
Shiwei.Yin@grayling.com
P. +1646 284-9474
Lucia Domville, Grayling
lucia.domville@grayling.com
P. +1646 284-9416
View original
content:http://www.prnewswire.com/news-releases/cure-pharmaceutical--therapix-biosciences-signs-mou-with-israels-assuta-medical-center-to-develop-first-in-class-therapeutic-products-in-fields-of-personalized-medicine--cannabinoids-300486025.html
SOURCE Therapix Biosciences